BUSINESS

Santen’s Myopia Drug Approved in Europe

June 6, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Santen Pharmaceutical said on June 5 that it has secured European regulatory approval for its low-dose atropine eye drop Ryjunea (atropine sulfate) for slowing the progression of pediatric myopia. The European Commission handed out its go-ahead for the drug to…

To read the full story

Santen’s Myopia Drug Ryjunea Now Available in Germany
July 23, 2025
Santen’s Myopia Drug Recommended for European Approval
April 1, 2025

BUSINESS

Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
Sumitomo to Launch Post-Marketing Study for iPSC Therapy by Year-End
March 9, 2026
Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
Nitrosamine Detected in Nichi-Iko’s Tryptanol, No Need to Halt Prescriptions
March 9, 2026
Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…